New drug duo tested to keep aggressive lung cancer at bay
NCT ID NCT07485920
Summary
This study is testing whether adding two drugs, tislelizumab and nintedanib, can help people with limited-stage small cell lung cancer live longer without their cancer getting worse. The drugs are given after patients finish their standard chemotherapy and radiation treatment. The goal is to see if this combination is safe and effective at controlling the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Qingdao Central Hospital Affiliated to Rehabilitation University
Qingdao, Shandong, China
Contact Email: •••••@•••••
-
Qingdao Municipal Hospital
Qingdao, Shandong, China
Contact Email: •••••@•••••
-
Weihai Municipal Hospital
Weihai, Shandong, China
Contact Email: •••••@•••••
-
Yantai Yuhuangding Hospital
Yantai, Shandong, China
Contact Email: •••••@•••••
-
Zibo Fourth People's Hospital
Zibo, Shandong, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.